- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 ; volume:19 ; number:1 ; day:7 ; month:4 ; year:2021 ; pages:1-17 ; date:12.2021
Journal of translational medicine ; 19, Heft 1 (7.4.2021), 1-17, 12.2021
- Urheber
-
Ascierto, Paolo A.
Atkins, Michael B.
Eggermont, Alexander M.
Gershenwald, Jeffrey E.
Grob, Jean-Jacques
Hamid, Omid
Sondak, Vernon K.
Sosman, Jeffrey A.
Tawbi, Hussein A.
Weber, Jeffrey S.
Caracò, Corrado
Osman, Iman
Puzanov, Igor
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-021-02808-3
- URN
-
urn:nbn:de:101:1-2021052908224442136056
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ascierto, Paolo A.
- Atkins, Michael B.
- Eggermont, Alexander M.
- Gershenwald, Jeffrey E.
- Grob, Jean-Jacques
- Hamid, Omid
- Sondak, Vernon K.
- Sosman, Jeffrey A.
- Tawbi, Hussein A.
- Weber, Jeffrey S.
- Caracò, Corrado
- Osman, Iman
- Puzanov, Igor
- SpringerLink (Online service)
Ähnliche Objekte (12)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020
Melanoma: A model for testing new agents in combination therapies
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020
Melanoma: A model for testing new agents in combination therapies
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
The “Great Debate” at Immunotherapy Bridge 2020, December 3rd, 2020
Melanoma: A model for testing new agents in combination therapies
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application